Scribe Therapeutics, Inc.

Scribe Therapeutics Inc. is a clinical-stage biotechnology company that researches and develops genetic medicines using CRISPR-based tools. The company aims to address the root cause of diseases, primarily focusing on cardiometabolic conditions within the United States. Scribe Therapeutics offers several key programs. STX-1150 is designed as a single-course in vivo epigenetic silencing treatment that targets the PCSK9 gene. STX-1200 is a CRISPR-based gene editing program intended to provide a permanent solution for patients with elevated Lp(a). Additionally, STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene, aiming to strongly reduce mRNA expression. The company utilizes CRISPR-based platforms, including ELXR, which is designed for precise, durable epigenetic silencing of genes without altering the underlying DNA sequence, and XE, which is designed to support specific and efficient gene editing. Scribe Therapeutics Inc. was incorporated in 2017 and is headquartered in Alameda, California.